SCHEMBL1306905

SCHEMBL1306905

CN(C)CCOc1cc(Cl)ccc1CN

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.49
GAA P10253 1/20 0.49
MAPK1 P28482 1/20 0.49
MAPT P10636 1/20 0.47
KEAP1 Q14145 1/20 0.45
NFE2L2 Q16236 1/20 0.45
NR4A2 P43354 2/20 0.44
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
KMT2A Q03164 1/20 0.43
CHRNB2 P17787 1/20 0.42
CHRNA4 P43681 1/20 0.42
HTR7 P34969 1/20 0.41
DRD2 P14416 1/20 0.41
DRD1 P21728 1/20 0.41
DRD4 P21917 1/20 0.41
DRD5 P21918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8139321 0.86 KDM4E (0.53) KDM4EGAAMAPK1MAPTNR4A2
SCHEMBL1308077 0.81 HTR2C (0.50) KDM4EMAPK1MAPTALDH1A1LMNA
SCHEMBL5099936 0.80 LMNA (0.43) KDM4EGAAMAPK1MAPTNR4A2
SCHEMBL1308133 0.79 HTT (0.46) KDM4EMAPK1MAPTALDH1A1SMN1; SMN2
SCHEMBL1306477 0.79 ALDH1A1 (0.45) MAPK1MAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL18773673 0.79 KDM4E (0.52) KDM4EGAAMAPK1MAPTNR4A2
SCHEMBL16544019 0.78 HTR2C (0.47) KDM4EMAPK1MAPTALDH1A1MEN1
SCHEMBL2552235 0.78 KDM4E (0.48) KDM4EKEAP1NFE2L2HTR7DRD2
SCHEMBL1306792 0.78 LMNA (0.48) KDM4EMAPK1MAPTALDH1A1SMN1; SMN2
SCHEMBL31641561 0.78 HTR7 (0.60) KDM4EGAAMAPK1MAPTNR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8053457-B2 3-imidazolyl-indoles for the treatment of proliferative diseases NOVARTIS AG (CH) 2011-11-08 US disclosed
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases NOVARTIS AG (CH) 2010-05-20 US disclosed
EP-2142535-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis Ag (CH) 2010-01-13 EP disclosed
WO-2008119741-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases MDM4, TP53, MDM2 KDM4E 920/4885GAA 3947/4885MAPK1 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.